We sought to determine if hyperglycemia directly increases intestinal epithelial permeability, and if any glucose-induced effects may be prevented pharmacologically with the FDA-approved PPARα agonist, fenofibrate. This evidence concerns the gene PPARA and Hyperglycemia.